Natural history of infantile-onset spinal muscular atrophy

the NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Objective: Infantile-onset spinal muscular atrophy (SMA) is the most common genetic cause of infant mortality, typically resulting in death preceding age 2. Clinical trials in this population require an understanding of disease progression and identification of meaningful biomarkers to hasten therapeutic development and predict outcomes. Methods: A longitudinal, multicenter, prospective natural history study enrolled 26 SMA infants and 27 control infants aged <6 months. Recruitment occurred at 14 centers over 21 months within the NINDS-sponsored NeuroNEXT (National Network for Excellence in Neuroscience Clinical Trials) Network. Infant motor function scales (Test of Infant Motor Performance Screening Items [TIMPSI], The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders, and Alberta Infant Motor Score) and putative physiological and molecular biomarkers were assessed preceding age 6 months and at 6, 9, 12, 18, and 24 months with progression, correlations between motor function and biomarkers, and hazard ratios analyzed. Results: Motor function scores (MFS) and compound muscle action potential (CMAP) decreased rapidly in SMA infants, whereas MFS in all healthy infants rapidly increased. Correlations were identified between TIMPSI and CMAP in SMA infants. TIMPSI at first study visit was associated with risk of combined endpoint of death or permanent invasive ventilation in SMA infants. Post-hoc analysis of survival to combined endpoint in SMA infants with 2 copies of SMN2 indicated a median age of 8 months at death (95% confidence interval, 6, 17). Interpretation: These data of SMA and control outcome measures delineates meaningful change in clinical trials in infantile-onset SMA. The power and utility of NeuroNEXT to provide “real-world,” prospective natural history data sets to accelerate public and private drug development programs for rare disease is demonstrated. Ann Neurol 2017;82:883–891.

Original languageEnglish (US)
Pages (from-to)883-891
Number of pages9
JournalAnnals of Neurology
Volume82
Issue number6
DOIs
StatePublished - Dec 1 2017

Fingerprint

Spinal Muscular Atrophies of Childhood
Spinal Muscular Atrophy
Biomarkers
Clinical Trials
Natural History
Action Potentials
National Institute of Neurological Disorders and Stroke
Muscles
Alberta
Infant Mortality
Survival Analysis
Neurosciences
Rare Diseases

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

the NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators (2017). Natural history of infantile-onset spinal muscular atrophy. Annals of Neurology, 82(6), 883-891. https://doi.org/10.1002/ana.25101

Natural history of infantile-onset spinal muscular atrophy. / the NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators.

In: Annals of Neurology, Vol. 82, No. 6, 01.12.2017, p. 883-891.

Research output: Contribution to journalArticle

the NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators 2017, 'Natural history of infantile-onset spinal muscular atrophy', Annals of Neurology, vol. 82, no. 6, pp. 883-891. https://doi.org/10.1002/ana.25101
the NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators. Natural history of infantile-onset spinal muscular atrophy. Annals of Neurology. 2017 Dec 1;82(6):883-891. https://doi.org/10.1002/ana.25101
the NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators. / Natural history of infantile-onset spinal muscular atrophy. In: Annals of Neurology. 2017 ; Vol. 82, No. 6. pp. 883-891.
@article{181e37bf1df743319b7486542d9b9677,
title = "Natural history of infantile-onset spinal muscular atrophy",
abstract = "Objective: Infantile-onset spinal muscular atrophy (SMA) is the most common genetic cause of infant mortality, typically resulting in death preceding age 2. Clinical trials in this population require an understanding of disease progression and identification of meaningful biomarkers to hasten therapeutic development and predict outcomes. Methods: A longitudinal, multicenter, prospective natural history study enrolled 26 SMA infants and 27 control infants aged <6 months. Recruitment occurred at 14 centers over 21 months within the NINDS-sponsored NeuroNEXT (National Network for Excellence in Neuroscience Clinical Trials) Network. Infant motor function scales (Test of Infant Motor Performance Screening Items [TIMPSI], The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders, and Alberta Infant Motor Score) and putative physiological and molecular biomarkers were assessed preceding age 6 months and at 6, 9, 12, 18, and 24 months with progression, correlations between motor function and biomarkers, and hazard ratios analyzed. Results: Motor function scores (MFS) and compound muscle action potential (CMAP) decreased rapidly in SMA infants, whereas MFS in all healthy infants rapidly increased. Correlations were identified between TIMPSI and CMAP in SMA infants. TIMPSI at first study visit was associated with risk of combined endpoint of death or permanent invasive ventilation in SMA infants. Post-hoc analysis of survival to combined endpoint in SMA infants with 2 copies of SMN2 indicated a median age of 8 months at death (95{\%} confidence interval, 6, 17). Interpretation: These data of SMA and control outcome measures delineates meaningful change in clinical trials in infantile-onset SMA. The power and utility of NeuroNEXT to provide “real-world,” prospective natural history data sets to accelerate public and private drug development programs for rare disease is demonstrated. Ann Neurol 2017;82:883–891.",
author = "{the NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators} and Kolb, {Stephen J.} and Coffey, {Christopher S.} and Yankey, {Jon W.} and Kristin Krosschell and Arnold, {W. David} and Rutkove, {Seward B.} and Swoboda, {Kathryn J.} and Reyna, {Sandra P.} and Ai Sakonju and Darras, {Basil T.} and Richard Shell and Nancy Kuntz and Diana Castro and Julie Parsons and Connolly, {Anne M.} and Chiriboga, {Claudia A.} and Craig McDonald and Burnette, {W. Bryan} and Klaus Werner and Mathula Thangarajh and Shieh, {Perry B.} and Erika Finanger and Cudkowicz, {Merit E.} and McGovern, {Michelle M.} and McNeil, {D. Elizabeth} and Richard Finkel and Iannaccone, {Susan T.} and Edward Kaye and Allison Kingsley and Renusch, {Samantha R.} and McGovern, {Vicki L.} and Xueqian Wang and Zaworski, {Phillip G.} and Prior, {Thomas W.} and Burghes, {Arthur H.M.} and Amy Bartlett and Kissel, {John T.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1002/ana.25101",
language = "English (US)",
volume = "82",
pages = "883--891",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Natural history of infantile-onset spinal muscular atrophy

AU - the NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators

AU - Kolb, Stephen J.

AU - Coffey, Christopher S.

AU - Yankey, Jon W.

AU - Krosschell, Kristin

AU - Arnold, W. David

AU - Rutkove, Seward B.

AU - Swoboda, Kathryn J.

AU - Reyna, Sandra P.

AU - Sakonju, Ai

AU - Darras, Basil T.

AU - Shell, Richard

AU - Kuntz, Nancy

AU - Castro, Diana

AU - Parsons, Julie

AU - Connolly, Anne M.

AU - Chiriboga, Claudia A.

AU - McDonald, Craig

AU - Burnette, W. Bryan

AU - Werner, Klaus

AU - Thangarajh, Mathula

AU - Shieh, Perry B.

AU - Finanger, Erika

AU - Cudkowicz, Merit E.

AU - McGovern, Michelle M.

AU - McNeil, D. Elizabeth

AU - Finkel, Richard

AU - Iannaccone, Susan T.

AU - Kaye, Edward

AU - Kingsley, Allison

AU - Renusch, Samantha R.

AU - McGovern, Vicki L.

AU - Wang, Xueqian

AU - Zaworski, Phillip G.

AU - Prior, Thomas W.

AU - Burghes, Arthur H.M.

AU - Bartlett, Amy

AU - Kissel, John T.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Objective: Infantile-onset spinal muscular atrophy (SMA) is the most common genetic cause of infant mortality, typically resulting in death preceding age 2. Clinical trials in this population require an understanding of disease progression and identification of meaningful biomarkers to hasten therapeutic development and predict outcomes. Methods: A longitudinal, multicenter, prospective natural history study enrolled 26 SMA infants and 27 control infants aged <6 months. Recruitment occurred at 14 centers over 21 months within the NINDS-sponsored NeuroNEXT (National Network for Excellence in Neuroscience Clinical Trials) Network. Infant motor function scales (Test of Infant Motor Performance Screening Items [TIMPSI], The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders, and Alberta Infant Motor Score) and putative physiological and molecular biomarkers were assessed preceding age 6 months and at 6, 9, 12, 18, and 24 months with progression, correlations between motor function and biomarkers, and hazard ratios analyzed. Results: Motor function scores (MFS) and compound muscle action potential (CMAP) decreased rapidly in SMA infants, whereas MFS in all healthy infants rapidly increased. Correlations were identified between TIMPSI and CMAP in SMA infants. TIMPSI at first study visit was associated with risk of combined endpoint of death or permanent invasive ventilation in SMA infants. Post-hoc analysis of survival to combined endpoint in SMA infants with 2 copies of SMN2 indicated a median age of 8 months at death (95% confidence interval, 6, 17). Interpretation: These data of SMA and control outcome measures delineates meaningful change in clinical trials in infantile-onset SMA. The power and utility of NeuroNEXT to provide “real-world,” prospective natural history data sets to accelerate public and private drug development programs for rare disease is demonstrated. Ann Neurol 2017;82:883–891.

AB - Objective: Infantile-onset spinal muscular atrophy (SMA) is the most common genetic cause of infant mortality, typically resulting in death preceding age 2. Clinical trials in this population require an understanding of disease progression and identification of meaningful biomarkers to hasten therapeutic development and predict outcomes. Methods: A longitudinal, multicenter, prospective natural history study enrolled 26 SMA infants and 27 control infants aged <6 months. Recruitment occurred at 14 centers over 21 months within the NINDS-sponsored NeuroNEXT (National Network for Excellence in Neuroscience Clinical Trials) Network. Infant motor function scales (Test of Infant Motor Performance Screening Items [TIMPSI], The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders, and Alberta Infant Motor Score) and putative physiological and molecular biomarkers were assessed preceding age 6 months and at 6, 9, 12, 18, and 24 months with progression, correlations between motor function and biomarkers, and hazard ratios analyzed. Results: Motor function scores (MFS) and compound muscle action potential (CMAP) decreased rapidly in SMA infants, whereas MFS in all healthy infants rapidly increased. Correlations were identified between TIMPSI and CMAP in SMA infants. TIMPSI at first study visit was associated with risk of combined endpoint of death or permanent invasive ventilation in SMA infants. Post-hoc analysis of survival to combined endpoint in SMA infants with 2 copies of SMN2 indicated a median age of 8 months at death (95% confidence interval, 6, 17). Interpretation: These data of SMA and control outcome measures delineates meaningful change in clinical trials in infantile-onset SMA. The power and utility of NeuroNEXT to provide “real-world,” prospective natural history data sets to accelerate public and private drug development programs for rare disease is demonstrated. Ann Neurol 2017;82:883–891.

UR - http://www.scopus.com/inward/record.url?scp=85038413158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038413158&partnerID=8YFLogxK

U2 - 10.1002/ana.25101

DO - 10.1002/ana.25101

M3 - Article

C2 - 29149772

AN - SCOPUS:85038413158

VL - 82

SP - 883

EP - 891

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 6

ER -